LXRX
Lexicon Pharmaceuticals Inc (LXRX)
Healthcare • NASDAQ • $2.22+2.78%
- Symbol
- LXRX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.22
- Daily Change
- +2.78%
- Market Cap
- $892.83M
- Trailing P/E
- N/A
- Forward P/E
- -9.74
- 52W High
- $2.53
- 52W Low
- $0.72
- Analyst Target
- $3.77
- Dividend Yield
- N/A
- Beta
- 1.07
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometab…
Company websiteResearch LXRX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.